Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 9Terminated 6Recruiting 6Withdrawn 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1

Conditions

Lymphoma 128Leukemia, Lymphocytic, Chronic, B-Cell 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Lymphoma, Non-Hodgkin 83Lymphoma, Follicular 76Lymphoma, Large B-Cell, Diffuse 71Leukemia 60Lymphoma, Mantle-Cell 51Burkitt Lymphoma 48Hodgkin Disease 44Leukemia, Myeloid, Acute 42Lymphoma, B-Cell, Marginal Zone 41Lymphoma, B-Cell 40Recurrence 38Lymphoma, T-Cell, Cutaneous 27Mycosis Fungoides 26Myelodysplastic Syndromes 25Waldenstrom Macroglobulinemia 24Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 24Multiple Myeloma 21Lymphoma, Large-Cell, Immunoblastic 21Lymphoma, Large-Cell, Anaplastic 21Sezary Syndrome 19Neoplasms 19Hematologic Neoplasms 18Myeloproliferative Disorders 17Lymphoma, Extranodal NK-T-Cell 16Leukemia, Myelomonocytic, Chronic 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Leukemia, Biphenotypic, Acute 14

Interventions

3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Epstein-Barr Virus Infections × Lymphoid × Clear all
NCT02229981 2017-12-07

ABC-102

RedHill Biopharma Limited

Phase 1/2 Withdrawn
LymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Sarcoma, Kaposi, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT01704742 2016-11-08

Prospective Study of Lymphoproliferative Diseases

West Virginia University

Withdrawn
Lymphoid

Acquired Immunodeficiency Syndrome, Hodgkin Disease, Lymphoma, Non-Hodgkin, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡